Back to Search
Start Over
Therapeutic Advances in Diabetic Nephropathy.
- Source :
-
Journal of clinical medicine [J Clin Med] 2022 Jan 13; Vol. 11 (2). Date of Electronic Publication: 2022 Jan 13. - Publication Year :
- 2022
-
Abstract
- Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin-angiotensin-aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease.
Details
- Language :
- English
- ISSN :
- 2077-0383
- Volume :
- 11
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of clinical medicine
- Publication Type :
- Academic Journal
- Accession number :
- 35054076
- Full Text :
- https://doi.org/10.3390/jcm11020378